Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1203 plus mFOLFOX6 versus placebo plus mFOLFOX6 in RAS/BRAF wild-type metastatic colorectal cancer
CTR20191318Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ql1203 in metastatic colorectal adenocarcinoma (mCRC), sponsored by Qilu Pharmaceutical. Started Apr 2020; status: active.
02
Drugs
ql1203
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20191318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191318.